Pan Tumor Rollover Study
Cancer
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2.6
2 insiders sold shares within a month
Since Sep 9, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 2
- Patients
- 1,500 (planned)
- Started
- Aug 9, 2019
- Main results expected
- Aug 25, 2029
- Fully finished
- Aug 25, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Incidence of Adverse Events (AEs)
Measured over: From Day 1 up to 135 Days after discontinuation of treatment
Incidence of drug related AEs
Measured over: From Day 1 up to 135 Days after discontinuation of treatment
Incidence of AEs leading to Discontinuation
Measured over: From Day 1 up to 135 Days after discontinuation of treatment
Incidence of Serious Adverse Events (SAEs)
Measured over: From signature of Informed Consent up to 135 Days after discontinuation of treatment
Incidence of Select AEs
Measured over: From Day 1 up to 135 Days after discontinuation of treatment
Incidence of Immune-Mediated AEs
Measured over: From Day 1 up to 135 Days after discontinuation of treatment
Incidence of Death
Measured over: From signature of Informed Consent up to 135 Days after discontinuation of treatment
Changes Tremor has spotted
Paperwork edit (contacts, locations, wording). Usually harmless.
Spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2.6, since 2026-09-09, fades (half-life)
Raw record changes
- 2026-11-06 15:29 UTC · paperwork · other
old: null
new: null
details: {"sections":["contactsLocationsModule","statusModule"]}
Trial ID NCT03899155 · record last updated 2026-11-06 · checked 2026-11-09 15:36 UTC